Independent Survival Indicator ID’d for Idiopathic Pulmonary Fibrosis
For patients with idiopathic pulmonary fibrosis (IPF), fat-free mass index (FFMI) predicts survival, according to a study published online in Respirology.
Diagnosis & Disease Information
Aerosurf Fast Tracked for RDS in Premature Infants
The FDA has granted Fast Track designation to Aerosurf (lucinactant for inhalation; Windtree Therapeutics) for the treatment of respiratory distress syndrome (RDS) in premature infants.
Surfactant Admin at 36 weeks and 1 year Examined in Trial
Late administration of surfactant does not reduce the duration of ventilation in very preterm neonates with prolonged respiratory distress, according to research published online February 29 in JAMA Pediatrics.
Study Examines Interstitial Lung Abnormalities Affect on Mortality
Interstitial lung abnormalities correlate with increased risk of all-cause mortality, according to research published in the Journal of the American Medical Association.
Emphysema Patients Benefit From Lung Volume Reduction Tx
Lung volume reduction coil treatment may help improve the ability to exercise for patients with severe emphysema, according to a study published in the January 12 issue of the Journal of the American Medical Association.
Excess Relative Risk of Repeat CT Scans Can Be Quantified
Recent publication demonstrates that very low doses repeated over time as harmful as acute exposure
Gene Therapy Found to Improve Lung Function in CF
Gene therapy showed a significant benefit in lung function in patients with cystic fibrosis, data from a Phase 2 trial has shown.
Expanded Age Range for Kalydeco Now Approved
Vertex Pharmaceuticals announced that the Food and Drug Administration (FDA) has approved Kalydeco (ivacaftor) for use in children ages 2-5 with cystic fibrosis (CF) who have one of 10 mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Pulmozyme with eRapid Nebulizer Use Approved for CF
The Food and Drug Administration (FDA) has approved PARI’s eRapid Nebulizer System (eRapid), the first electronic nebulizer to deliver Pulmozyme (dornase alfa [recombinant human DNase]; Genentech) for the treatment of cystic fibrosis.
Lumacaftor + Ivacaftor NDA Submitted for Cystic Fibrosis
Vertex announced that it has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for the combination product lumacaftor and ivacaftor for people with cystic fibrosis (CF) ages ≥12 who have two copies of the F508del mutation in the cystic fibrosis transmembrance conductance regulator (CFTR) gene.
